Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J)

BMC Cardiovascular Disorders

Volumn 6, Issue , 2006, Pages

  Kawamori, Ryuzo ^a   Daida, Hiroyuki ^a   Tanaka, Yasushi ^b   Miyauchi, Katsumi ^a   Kitagawa, Akira ^c   Hayashi, Dobun ^d   Kishimoto, Junji ^e   Ikeda, Shunya ^c   Imai, Yutaka ^f   Yamazaki, Tsutomu ^d  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIN; AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; LOSARTAN POTASSIUM; NU LOTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DRUG DOSE REGIMEN; HUMAN; HYPERTENSION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TREATMENT OUTCOME;

ADULT; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RESEARCH DESIGN;

EID: 33750309467     PISSN: 14712261     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-6-39     Document Type: Article

References (28)

1. Design, Rationale, and Objectives of The Framingham Heart Study [http://www.nhlbi.nih.gov/about/framingham/design.htm]
2. Epstein M, Sowers JR: Diabetes mellitus and hypertension. Hypertension 1992, 19:403-418.
3. Grossman E, Messerli FH: Diabetic and hypertensive heart disease. Ann Intern Med 1996, 125:304-310.
4. American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2002, 25(Suppl 1):S71-73.
5. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713-720.
6. Hansson L, Zanchetti A. Carruthers SG, Bjdsorn Dahlöf, Elmfeldt D, Julius S, Ménqrd J, Rahn KH, Wedel H, Westerling WS: Effects of intensive blood-pressure lowering and aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
7. American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2002, 25(Suppl 1):S71-73.
8. Chobanian AV, Barkis GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ: the National High Blood Pressure Education Program Coordination, Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003, 289:2560-2572.
9. Guideline Committee: 2003 European Society of European Hypertension-European Society of Cardiology guideline for the management of arterial hypertension. J Hypetens 2003, 21:1011-1053.
10. Yki-Järvinen H: Management of type 2 diabetes mellitus and cardiovascular risk. Lessons from intervention trials. Drugs 2000, 60:975-983. [PubMed Abstract]
11. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaäki K, Björn Dahlöf, de Faire U, Claes Mörlin, Karlberg BE, Wester PO, Björck J-E: Effect of angiotensin converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Projects (CAPPP) randomised trial. Lancet 1999, 353:611-616.
12. Björn Dahlöf, Devareux RB, Kjedsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
13. Timmermann PB: Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res 1999, 22:147-53.
14. Dahlöf B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY: Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995, 8:578-83.
15. Hansson L, Lindholm LH, Ekbom T: Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-56.
16. Mulrow C, Lau J, Cornell J, Brand M: Pharmacotherapy for hypertension in the elderly (Cochrane review). In The Cochrane Library Issue 2 Oxford: Update Software; 2001.
17. The Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Eng J Med 1981, 304:801-7.
18. First International Study of Infarct Survival Collaborative Group: Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986, 2:57-66.
19. Tumoliehto J, Rastenyte D, Birkenhanger WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A. Palatini P, Sarti C, Fagard R: Effect of calcium-channel blockade in order patients with diabetes and systolic hypertensiton. N Engl J Med 1999, 340:677-684.
20. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin independent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
21. Epstein M: Calcium antagonists and renal protection: current status and future perspectives. Arch Intern Med 1992, 152:1573-84.
22. Giugliano D, De Rosa N, Marfella. R: Comparison of nitrendipine and cilazapril in patients with hypertension and non-insulin dependent diabetes mellitus. Am J Hypertens 1993, 6:927-32.
23. Furberg CD, Psaty BM, Meyer JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1326-31.
24. Tatti P, Pahor M, Byington RB: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597-603.
25. Alderman M, Madhavan S, Cohen H: Calcium antagonists and cardiovascular events in patients with hypertension and diabetes. Lancet 1998, 351:216-7.
26. Byington RP, Craven TE, Furberg CD, Pahor M: Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 1998, 350:1075-6.
27. Pahor M, Kritchevsky SB, Zuccala G, Guralnik JM: Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998, 21:193-4.
28. Pahor M, Psaty BM, Furberg CD: Treatment f hypertensive patients with diabetes. Lancet 1998, 351:689-90.